RxDoctor Payments Data

Mohammad Arain, MD

Internal Medicine · Santa Maria, CANPI 1639167158

Payments from drug & device makers

$2,234in general payments, 2019–2025

Across 127 payments — averaging $17.59 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Pfizer$708
  • Amgen$445
  • GSK$203
  • E.r. Squibb & Sons, L.L.C.$127
  • Exact Sciences$111
  • Novo Nordisk$99
  • plus $542 from 14 others

What the payments were for

  • Food & beverage$2,234100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,234 in reported general payments places this provider in the 80th percentile of 13,581 internal medicine providers in California.

See all internal medicine providers in California

Medicare billing

Part B allowed, 2024
$451,620
Medicare patients
382
Services billed
24,199

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban129$99,049
XareltoRivaroxaban54$45,340
JanuviaSitagliptin Phosphate47$38,715
Trelegy ElliptaFluticasone/Umeclidin/Vilanter27$17,907
JardianceEmpagliflozin16$17,716
Tresiba Flextouch U-100Insulin Degludec11$8,934
MyrbetriqMirabegron11$7,044
Arnuity ElliptaFluticasone Furoate19$5,498
Atorvastatin Calcium537$5,075
Diclofenac Sodium347$4,874
Rosuvastatin Calcium180$4,042
Lantus SolostarInsulin Glargine,hum.Rec.Anlog53$3,905
Levothyroxine Sodium283$3,724
Memantine Hcl84$3,446
Tamsulosin Hcl209$3,191

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$708$99,049129 claims
Johnson & JohnsonXarelto$66$45,34054 claims
MerckJanuvia$23$38,71547 claims
GSKTrelegy Ellipta, Arnuity Ellipta$203$23,40446 claims
Boehringer IngelheimJardiance$46$17,71616 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 13,581 internal medicine providers in California.

Other internal medicine in Santa Maria

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →